X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2129) 2129
Publication (374) 374
Newsletter (82) 82
Book Review (69) 69
Newspaper Article (20) 20
Transcript (10) 10
Book Chapter (7) 7
Government Document (5) 5
Book / eBook (4) 4
Magazine Article (3) 3
Conference Proceeding (2) 2
Reference (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
buprenorphine (1801) 1801
humans (1188) 1188
index medicus (1122) 1122
male (978) 978
female (843) 843
methadone (669) 669
substance abuse (625) 625
adult (607) 607
psychiatry (543) 543
animals (502) 502
buprenorphine - therapeutic use (478) 478
pharmacology & pharmacy (478) 478
opioids (460) 460
buprenorphine - administration & dosage (365) 365
middle aged (349) 349
morphine (341) 341
narcotics (314) 314
buprenorphine - pharmacology (308) 308
opioid-related disorders - drug therapy (307) 307
article (300) 300
care and treatment (300) 300
drug use (295) 295
drug abuse (291) 291
pain (283) 283
heroin (273) 273
analysis (269) 269
rats (264) 264
drug interactions (263) 263
dose-response relationship, drug (259) 259
opioid dependence (251) 251
methadone - therapeutic use (247) 247
dependency (240) 240
addiction (226) 226
narcotic antagonists - therapeutic use (225) 225
treatment outcome (224) 224
neurosciences (223) 223
analgesics, opioid - therapeutic use (222) 222
substance abuse treatment (221) 221
analgesics, opioid - administration & dosage (219) 219
pharmacotherapy (207) 207
buprenorphine - adverse effects (205) 205
naloxone (205) 205
opioid-related disorders - rehabilitation (192) 192
dependence (191) 191
research (188) 188
drugs (182) 182
analgesia (172) 172
maintenance (171) 171
usa (169) 169
cocaine (168) 168
drug therapy (163) 163
pharmacokinetics (162) 162
analgesics, opioid - adverse effects (161) 161
pharmacology (161) 161
young adult (160) 160
abuse (159) 159
analgesics (158) 158
analgesics, opioid - pharmacology (154) 154
pregnancy (153) 153
double-blind method (148) 148
methadone-maintenance (138) 138
naltrexone (136) 136
veterinary sciences (136) 136
treatment (135) 135
psychology, clinical (134) 134
opiate substitution treatment - methods (131) 131
clinical trials (128) 128
mice (123) 123
narcotic antagonists - administration & dosage (121) 121
buprenorphine - pharmacokinetics (120) 120
dosage and administration (119) 119
time factors (118) 118
health aspects (115) 115
methadone - administration & dosage (115) 115
adolescent (113) 113
fentanyl (111) 111
hiv (111) 111
drug therapy, combination (109) 109
aged (108) 108
opioid (106) 106
pain - drug therapy (106) 106
management (103) 103
narcotics - therapeutic use (102) 102
opioid-related disorders - psychology (102) 102
patients (102) 102
clinical neurology (101) 101
usage (101) 101
maintenance treatment (100) 100
detoxification (99) 99
methadone - adverse effects (98) 98
opiate substitution treatment (98) 98
united-states (98) 98
withdrawal (98) 98
methadone hydrochloride (96) 96
opioid-related disorders - epidemiology (95) 95
treatment outcomes (95) 95
medicine (93) 93
narcotic antagonists - pharmacology (93) 93
drug addiction (90) 90
pain management (90) 90
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2229) 2229
French (12) 12
German (10) 10
Japanese (4) 4
Spanish (4) 4
Danish (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 4, pp. 792 - 800
Summary Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other... 
Gastroenterology and Hepatology | Boceprevir | Hepatitis C virus infection | Telaprevir | Pharmacokinetics | Drug interactions | CHRONIC HEPATITIS-C | GASTROENTEROLOGY & HEPATOLOGY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hepatitis C, Chronic - metabolism | Antiviral Agents - pharmacokinetics | Hypnotics and Sedatives - adverse effects | Humans | Hypnotics and Sedatives - administration & dosage | Drug Interactions | Hypoglycemic Agents - administration & dosage | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Cardiovascular Agents - administration & dosage | Anti-Infective Agents - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Opiate Substitution Treatment - adverse effects | Buprenorphine - administration & dosage | Anti-Infective Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Buprenorphine - adverse effects | Antidepressive Agents - administration & dosage | Immunosuppressive Agents - adverse effects | Methadone - administration & dosage | Methadone - adverse effects | Antidepressive Agents - adverse effects | Cardiovascular Agents - adverse effects | Hypoglycemic Agents - adverse effects | Hepatitis C virus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 09/2015, Volume 59, Issue 9, pp. 5503 - 5510
Journal Article
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 03/2018, Volume 107, Issue 3, pp. 942 - 948
CAM2038, FluidCrystal injection depot, is an extended release formulation of buprenorphine given subcutaneously every 1 week (Q1W) or every 4 weeks (Q4W). The... 
ketoconazole | buprenorphine | drug-drug interaction | rifampin | physiologically based pharmacokinetics | CYTOCHROME-P450 | CHEMISTRY, MEDICINAL | VOLUNTEERS | CHEMISTRY, MULTIDISCIPLINARY | BIOAVAILABILITY | SUBLINGUAL BUPRENORPHINE | IN-VITRO | NORBUPRENORPHINE | FORMULATIONS | METHADONE | PHARMACOLOGY & PHARMACY
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 2017, Volume 61, Issue 10
The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (formerly ABT-530), an NS5A... 
Pibrentasvir | Naloxone | Buprenorphine | Glecaprevir | HCV | Methadone | Pharmacokinetics | (R)-METHADONE | MICROBIOLOGY | buprenorphine | pibrentasvir | pharmacokinetics | naloxone | PHARMACOLOGY & PHARMACY | INFECTION | SCALE | methadone | HEPATITIS-C | glecaprevir
Journal Article
Toxicological Sciences, ISSN 1096-6080, 02/2017, Volume 155, Issue 2, pp. 389 - 399
Respiratory depression and fatalities have been attributed to ethanol/buprenorphine (BUP) combination in drug addicts maintained with BUP/naloxone or BUP... 
Naloxone | Respiratory depression | Buprenorphine | Ethanol | Pharmacokinetics | Plethysmography | respiratory depression | BENZODIAZEPINES | plethysmography | ALCOHOL-INTOXICATION | ethanol | NORBUPRENORPHINE | buprenorphine | PHARMACOLOGY | pharmacokinetics | naloxone | TOXICOLOGY | BINDING | SELECTIVITY | BOVINE SERUM-ALBUMIN
Journal Article
Drugs in R&D, ISSN 1174-5886, 9/2019, Volume 19, Issue 3, pp. 297 - 305
Researchers have long been interested in the potential drug–drug interactions (DDIs) between opioids and benzodiazepines. However, much remains unknown... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | OXYCODONE | DIAZEPAM | METABOLISM | BUPRENORPHINE | METHADONE | CYP2D6 | PHARMACOLOGY & PHARMACY | HUMAN LIVER | CYP3A4 | MIDAZOLAM | TRIAZOLAM | Original
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 08/2017, Volume 26, Issue 8, pp. 875 - 889
Purpose To assess whether a “drugome‐wide” screen with case‐crossover design is a feasible approach for identifying candidate drugs and drug‐drug interactions.... 
interaction | screening | hip fracture | drug‐drug | case‐crossover | drug | drug-drug | case-crossover | DIAGNOSIS | FINLAND | METAANALYSIS | COMMUNITY-DWELLING PERSONS | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | THERAPY | PRE2DUP | PHARMACOLOGY & PHARMACY | Acetaminophen - adverse effects | Drug Evaluation, Preclinical - methods | Humans | Middle Aged | Risk Factors | Risperidone - administration & dosage | Acetaminophen - administration & dosage | Codeine - adverse effects | Alzheimer Disease - drug therapy | Male | Hip Fractures - epidemiology | Alzheimer Disease - diagnosis | Cross-Over Studies | Codeine - administration & dosage | Drug Interactions - physiology | Risperidone - adverse effects | Aged, 80 and over | Adult | Alzheimer Disease - epidemiology | Female | Aged | Hip Fractures - diagnosis | Finland - epidemiology | Hip Fractures - chemically induced | Complications and side effects | Fractures | Buprenorphine | Antibacterial agents | Alzheimer's disease | Drug interactions | Drugs | Drug abuse | Olanzapine | Identification methods | Fentanyl | Trimethoprim | Risk | Drug development | Paracetamol | Diagnosis | Hydroxocobalamin | Hip joint | Metoprolol | Simvastatin | Health risks | Feasibility studies | Pharmacology | Medical screening | Hip | Codeine | Side effects | Memantine | Health hazards | Ciprofloxacin
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 1/2011, Volume 50, Issue 1, pp. 25 - 39
Etravirine (formerly TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant strains of HIV-1.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Drug-interactions | Ribavirin, drug interactions | Antiepileptic-drugs, drug interactions | Simvastatin, drug interactions | Voriconazole, drug interactions | Dexamethasone, drug interactions | Fibric-acid-derivatives, drug interactions | Rifampicin, drug interactions | Opioid-analgesics, drug interactions | Antidepressants, drug interactions | Atorvastatin, drug interactions | Antiretrovirals, drug interactions | Anti-infectives, drug interactions | Histamine-H2-receptor-antagonists, drug interactions | Diazepam, drug interactions | Ketoconazole, drug interactions | Fluconazole, drug interactions | Hypericum, drug interactions | HMG-CoA-reductase-inhibitors, drug interactions | Oral-contraceptives, drug interactions | Sildenafil, drug interactions | Omeprazole, drug interactions | Buprenorphine, drug interactions | Rosuvastatin, drug interactions | Non-nucleoside-reverse-transcriptase-inhibitors, drug interactions | Type-5-cyclic-nucleotide- phosphodiesterase-inhibitors, drug interactions | Corticosteroids, drug interactions | Paroxetine, drug interactions | Fluoxetine, drug interactions | Rifapentine, drug interactions | Ethinylestradiolnorethisterone, drug interactions | Ranitidine, drug interactions | Etravirine, drug interactions | Antifungals, drug interactions | Digoxin, drug interactions | Warfarin, drug interactions | Methadone, drug interactions | Fluvastatin, drug interactions | Rifabutin, drug interactions | Sertraline, drug interactions | Azithromycin, drug interactions | Pharmacokinetics | Calcineurin-inhibitors, drug interactions | Itraconazole, drug interactions | Proton-pump-inhibitors, drug interactions | Clarithromycin, drug interactions | TRANSCRIPTASE INHIBITOR ETRAVIRINE | METABOLISM | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | HIV-NEGATIVE VOLUNTEERS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | HUMAN LIVER | PLACEBO-CONTROLLED TRIAL | 2 DIFFERENT FORMULATIONS | CLINICAL PHARMACOKINETICS | Reverse Transcriptase Inhibitors - adverse effects | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Drug-Related Side Effects and Adverse Reactions | Humans | Pyridazines - pharmacokinetics | Drug Therapy, Combination | Pyridazines - adverse effects | Etravirine | Drug interactions | Physiological aspects | Dosage and administration | Research | Properties | Drug therapy | HIV infection
Journal Article